Medication info

Olbecaduo Tablets 5/40 Milligrams

Prescription medicationTabletOralExpired
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Youngil Pharmaceutical Co., Ltd.
Appearance
Pale yellow round film-coated tablets
Packaging
30 tablets / PTPI [(10 tablets / PTPI x 3)]
Approval status
Expired

MFDS item code 202002911 · Approved 2020.04.23

This product's status changed to Expired on 2025.04.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
This medicine is administered as 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should have their blood pressure and renal function closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See Precautions for Use, section 2. Patients Who Should Not Receive This Medicine.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbid conditions. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Youngil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively control blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy of amlodipine or olmesartan medoxomil.

How to take

Adult dose

This medicine is administered as 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should have their blood pressure and renal function closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See Precautions for Use, section 2. Patients Who Should Not Receive This Medicine.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbid conditions. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm or death to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. This medication should not be used in individuals who are allergic to the active ingredients or dihydropyridine derivatives, pregnant or breastfeeding women, patients with severe liver impairment or aortic stenosis, patients with biliary obstruction, patients on dialysis, patients in shock, certain diabetic patients, and patients with significantly impaired renal function. Patients with low blood volume or sodium levels may experience a significant drop in blood pressure at the beginning of treatment, so their condition should be closely monitored, and patients with heart or vascular issues should also use this medication cautiously due to the risk of rapid vasodilation leading to hypotension. This medication can cause various side effects such as dizziness, headache, hypotension, orthostatic hypotension, drowsiness, gastrointestinal symptoms, skin rash, and edema. If symptoms are severe, consult a physician, as serious side effects have also been reported occasionally. Sudden discontinuation of beta blockers can be risky, so if this medication is prescribed alongside beta blockers, they should be tapered off gradually. This medication can cause renal impairment or electrolyte imbalance in patients with poor kidney function or heart failure, necessitating regular monitoring. This medication should not be taken during pregnancy, and those planning to become pregnant or who are pregnant should consult a physician. Breastfeeding may result in the medication transferring to breast milk, potentially causing side effects in infants, so it may be advisable to discontinue breastfeeding or the medication. Safety and efficacy in children under 18 years have not been established, so it is not recommended for this age group. Elderly patients should start at a low dose and use cautiously due to potential renal and hepatic dysfunction. In case of overdose, symptoms may include hypotension and symptoms due to vasodilation, so immediate medical attention is necessary. This medication should be stored in a tightly closed container protected from direct sunlight and moisture, and it is best not to transfer it to another container.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and moisture, and it is important to maintain a storage temperature between 1 and 30 degrees Celsius. Therefore, it should be kept in a cool, dry place until use.

Appearance and packaging

Appearance

Pale yellow round film-coated tablets

Package unit

30 tablets / PTPI [(10 tablets / PTPI x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.